BioDelivery Sciences International
2501 Aerial Center Parkway
Suite 205
Morrisville
North Carolina
27560
United States
Tel: 919-651-5160
Fax: 919-651-5161
Website: http://www.bdsinternational.com/
365 articles about BioDelivery Sciences International
-
Collegium Completes the Acquisition of BDSI
3/22/2022
Collegium Pharmaceutical, Inc. announced that it has completed the acquisition of BioDelivery Sciences International Inc.
-
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
2/24/2022
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.
-
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
-
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
2/14/2022
BioDelivery Sciences International, Inc. today announced that it has entered into a definitive merger agreement for Collegium Pharmaceutical, Inc.
-
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio
2/14/2022
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.
-
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
1/20/2022
BioDelivery Sciences International, Inc. announced it expects 2021 total Company net revenues and BELBUCA® net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.
-
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
11/3/2021
BioDelivery Sciences International, Inc. today reported solid financial results for the third quarter ended September 30, 2021, including the following operational and performance highlights.
-
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
10/21/2021
BioDelivery Sciences International, Inc., a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.
-
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
10/20/2021
BioDelivery Sciences International, Inc. announced today that it will report its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 3, 2021.
-
BioDelivery Sciences International to Host ELYXYB™ Investor Day
9/30/2021
BioDelivery Sciences International, Inc., a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced it will host a virtual ELYXYB™ Investor Day on Thursday, October 14, 2021, at 10:30am ET.
-
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
9/9/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.
-
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference
9/7/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at the PAINWeek 2021 Conference taking place September 7 – 11, 2021 at The Cosmopolitan of Las Vegas.
-
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
9/3/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Executive Vice President and Chief Financial Officer, will present and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference
-
BioDelivery Sciences Reports Second Quarter 2021 Results
8/4/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June 30, 2021, including the following operational and performance highlights.
-
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
8/4/2021
The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036
-
BioDelivery Sciences Reports First Quarter 2021 Results
5/6/2021
Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today
-
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
4/20/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 6, 2021.
-
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
3/10/2021
Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today
-
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
2/17/2021
BioDelivery Sciences International, Inc., a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced that it will report its fourth quarter and full year 2020 financial results before the open of the U.S. financial markets on Wednesday, March 10, 2021.
-
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice PresidentBrings Track Record of Success to Expanded Role
2/11/2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer.